Adverse drug interactions involving common prescription and over-the-counter analgesic agents

Clinical Therapeutics

Volumn 29, Issue 11 SUPPL. 1, 2007, Pages 2477-2497

  Hersh, Elliot V ^a   Pinto, Andres ^a   Moore, Paul A ^b  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

acetaminophen; aspirin; celecoxib; codeine; drug interactions; hydrocodone; ibuprofen; naproxen; oxycodone; propoxyphene; tramadol

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CITALOPRAM; CODEINE; DEXTROPROPOXYPHENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOXETINE; HYDROCODONE; IBUPROFEN; LITHIUM; METHOTREXATE; MUSCLE RELAXANT AGENT; NAPROXEN; OXYCODONE; PARACETAMOL; PAROXETINE; PETHIDINE; PHENELZINE; QUINIDINE; SERTRALINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALDECOXIB; WARFARIN;

AGE; ARTHRITIS; ARTICLE; BLURRED VISION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE EXACERBATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PROTECTION; HUMAN; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MEDLINE; NAUSEA; PAIN; POSTOPERATIVE PAIN; PRESCRIPTION; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SEROTONIN SYNDROME; SINGLE DRUG DOSE; SKIN ALLERGY; THROMBOSIS; TREMOR; UNITED STATES; UNSTABLE ANGINA PECTORIS; VERTIGO;

ACETAMINOPHEN; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DRUG INTERACTIONS; DRUGS, NON-PRESCRIPTION; ETHANOL; HEALTH STATUS; HUMANS; LITHIUM COMPOUNDS; METHOTREXATE; SEROTONIN UPTAKE INHIBITORS; WARFARIN;

EID: 37349060627     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.12.003     Document Type: Article

References (178)

1. Lamb E. Top 200 prescription drugs of 2006. Pharm Times 73 (2007) 34-37
2. Sun B., Wu C., and Kalunian K. New developments in osteoarthritis. Rheum Dis Clin North Am 33 (2007) 135-148
3. Moore P., Nahouraii H., Zovko J., and Wisniewski S. Dental therapeutic practice patterns in the US. II. Analgesics, corticosteroids, and antibiotics. Gen Dent 54 (2006) 201-207
4. Gimbel J., Brugger A., Zhao W., et al. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther 23 (2001) 228-241
5. Verhagen A., Damen L., Berger M., et al. Is any one analgesic superior for episodic tension-type headache?. J Fam Pract 55 (2006) 1064-1072
6. Schachtel B., Furey S., and Thoden W. Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache. J Clin Pharmacol 36 (1996) 1120-1125
7. Mens J. The use of medication in low back pain. Best Pract Res Clin Rheumatol 19 (2005) 609-621
8. Zhang W., and Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: A systematic review. Br J Obstet Gynaecol 105 (1998) 780-789
9. Hewitt D., Todd K., Xiang J., et al., for the CAPSS-216 Study Investigators. Tramadol/acetaminophen or hydrocodone/acetaminophen for the treatment of ankle sprain: A randomized, placebo-controlled trial. Ann Emerg Med 49 (2007) 468-480
10. Hersh E., Moore P., and Ross G. Over-the-counter analgesics and antipyretics: A critical assessment. Clin Ther 22 (2000) 500-548
11. Wilcox C., Cryer B., and Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: Focus on nonsteroidal antiinflammatory drugs. J Rheumatol 32 (2005) 2218-2224
12. Patrono C. Aspirin: New cardiovascular uses for an old drug. Am J Med 110 (2001) 62S-65S
13. Gaziano J. Nonnarcotic analgesics and hypertension. Am J Cardiol 97 (2006) 10-16
14. Gaziano J., and Gibson C. Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection. Am J Cardiol 97 (2006) 23-29
15. Moore P., Gage T., Hersh E., et al. Adverse drug interactions in dental practice. Professional and educational implications. J Am Dent Assoc 130 (1999) 47-54
16. Spencer-Green G., and Spencer-Green E. Nonsteroidal therapy of rheumatoid arthritis and osteoarthritis: How physicians manage treatment failures. J Rheumatol 25 (1998) 2088-2093
17. Shi W., Wang Y., Li L., et al. Safety and efficacy of oral nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis: A six-month randomised study. Clin Drug Investig 24 (2004) 89-101
18. Silverstein F., Faich G., Goldstein J., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
19. Bombardier C., Laine L., Reicin A., et al., for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
20. Ackerman S., Mordin M., Reblando J., et al. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm 9 (2003) 223-231
21. Mucci-LoRusso P., Berman B., Silberstein P., et al. Controlled-release oxycodone compared with controlled- release morphine in the treatment of cancer pain: A randomized, double-blind, parallel-group study. Eur J Pain 2 (1998) 239-249
22. Kosinski M., Janagap C., Gajria K., et al. Pain relief and pain-related sleep disturbance with extended-release tramadol in patients with osteoarthritis. Curr Med Res Opin 23 (2007) 1615-1626
23. Beaulieu A., Peloso P., Bensen W., et al. A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain. Clin Ther 29 (2007) 49-60
24. Hermos J., Young M., Gagnon D., and Fiore L. Characterizations of long-term oxycodone/acetaminophen prescriptions in veteran patients. Arch Intern Med 164 (2004) 2361-2366
25. In: Stockley I. (Ed). Stockley's Drug Interactions. 6th ed (2002), Pharmaceutical Press, London, UK
26. Datta P., and Dasgupta A. A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is flee from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone. Ther Drug Monit 25 (2003) 478-482
27. Raebel M., Chester E., Newsom E., et al. Randomized trial to improve laboratory safety monitoring of ongoing drug therapy in ambulatory patients. Pharmacotherapy 26 (2006) 619-626
28. Chen K., Shen W., and Lu M. Implication of serum concentration monitoring in patients with lithium intoxication. Psychiatry Clin Neurosci 58 (2004) 25-29
29. Duncker A., and Greenberg S. A Profile of Older Americans: 2000 (2000), Administration on Aging, US Dept of Health and Human Services, Washington, DC
30. Nolan L., and O'Malley K. Prescribing for the elderly: Part II. Prescribing patterns: Differences due to age. J Am Geriatr Soc 36 (1988) 245-254
31. Turnheim K. Drug therapy in the elderly. Exp Gerontol 39 (2004) 1731-1738
32. Hersh E., and Moore P. Drug interactions in dentistry: The importance of knowing your CYPs. J Am Dent Assoc 135 (2004) 298-311
33. Kellstein D., Waksman J., Furey S., et al. The safety profile of non-prescription ibuprofen in multiple-dose use: A meta-analysis. J Clin Pharmacol 39 (1999) 520-532
34. DeArmond B., Francisco C., Lin J., et al. Safety profile of over-the-counter naproxen sodium. Clin Ther 17 (1995) 587-601
35. Henry D., Lim L., Garcia Rodriguez L., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. BMJ 312 (1996) 1563-1566
36. Lewis S., Langman M., Laporte J., et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: A meta-analysis based on individual patient data. Br J Clin Pharmacol 54 (2002) 320-326
37. Lewis J., Kimmel S., Localio A., et al. Risk of serious upper gastro-intestinal toxicity with over-the-counter nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 129 (2005) 1865-1874
38. Rumack B. Acetaminophen hepatotoxicity: The first 35 years. J Toxicol Clin Toxicol 40 (2002) 3-20
39. Schiodt F., Atillasoy E., Shakil A., et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 5 (1999) 29-34
40. Linnoila M., and Hakkinen S. Effects of diazepam and codeine, alone and in combination with alcohol, on simulated driving. Clin Pharmacol Ther 15 (1974) 368-373
41. Saarialho-Kere U., Mattila M., and Seppala T. Psychomotor, respiratory and neuroendocrinological effects of a mu-opioid receptor agonist (oxycodone) in healthy volunteers. Pharmacol Toxicol 65 (1989) 252-257
42. Burrows D., Hagardorn A., Harlan G., et al. A fatal drug interaction between oxycodone and clonazepam. J Forensic Sci 48 (2003) 683-686
43. Drummer O. Recent trends in narcotic deaths. Ther Drug Monit 27 (2005) 738-740
44. Huffman D., and Ferguson R. Acute codeine overdose: Correspondence between clinical course and codeine metabolism. Johns Hopkins Med J 136 (1975) 183-186
45. Forrest J., Clements J., and Prescott L. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet 7 (1982) 93-107
46. Slattery J., Nelson S., and Thummel K. The complex interaction between ethanol and acetaminophen. Clin Pharmacol Ther 60 (1996) 241-246
47. Critchley J., Dyson E., Scott A., et al. Is there a place for cimetidine or ethanol in the treatment of paracetamol poisoning?. Lancet 1 (1983) 1375-1376
48. Rumack B., Peterson R., Koch G., and Amara I. Acetaminophen overdose. 662 Cases with evaluation of oral acetylcysteine treatment. Arch Intern Med 141 (1981) 380-385
49. Thummel K., Slattery J., Ro H., et al. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther 67 (2000) 591-599
50. Linden C., and Rumack B. Acetaminophen overdose. Emerg Med Clin North Am 2 (1984) 103-119
51. Lauterburg B., and Velez M. Glutathione deficiency in alcoholics: Risk factor for paracetamol hepatotoxicity. Gut 29 (1988) 1153-1157
52. Dart R., Kuffner E., and Rumack B. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: A systematic review. Am J Ther 7 (2000) 123-134
53. Kuffner E., Green J., Bogdan G., et al. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients-a multicenter randomized study. BMC Med 5 (2007) 13
54. Food and Drug Administration, Dept of Health and Human Services. Over-the-counter drug products containing analgesic/antipyretic active ingredients for internal use. Required alcohol warning. Fed Reglst 63 (1998) 56789-56802
55. Hersh E., Lally E., and Moore P. Update of cyclooxygenase inhibitors: Has a third COX isoform entered the fray?. Curr Med Res Opin 21 (2005) 1217-1226
56. Pedersen A., and FitzGerald G. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311 (1984) 1206-1211
57. Crofford L. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol Suppl 49 (1997) 15-19
58. Knijff-Dutmer E., Kalsbeek-Batenburg E., Koerts J., and van de Laar M. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygen ase-2-selective inhibitots in patients with rheumatoid arthritis. Rheumatology (Oxford) 41 (2002) 458-461
59. Bresalier R., Sandier R., Quan H., et al., for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. [published correction appears in N Engl J Med. 2006;355:221]. N Engl J Med 352 (2005) 1092-1102
60. Nussmeier N., Whelton A., Brown M., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
61. FDA news: FDA announces series of changes to the class of marketed non-steroidal anti-inflammatory drugs (NSAIDs) [FDA Web site]
62. http://www.fda.gov/bbs/topics/news/2005/NEW01171.html Accessed August 7, 2007
63. Solomon S., McMurray J., Pfeffer M., et al., for the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
64. Jenkins JK, Seligman PJ. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk [FDA Web site]
65. http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf Accessed August 7, 2007
66. Bawurt N., Abasiyanik M., Sander E., and Salih B. Canonical correlation analysis of factors involved in the occurrence of peptic ulcers. Dig Dis Sci 52 (2007) 140-146
67. Goulston K., and Cooke A. Alcohol, aspirin, and gastrointestinal bleeding. BMJ 4 (1968) 644-645
68. DeSchepper P., Tjandramaga T., De Roo M., et al. Gastrointestinal blood loss after diflunisal and after aspirin: Effect of ethanol. Clin Pharmacol Ther 23 (1978) 669-676
69. Needham C., Kyle J., Jones P., et al. Aspirin and alcohol in gastrointestinal haemorrhage. Gut 12 (1971) 819-821
70. Kaufman D., Kelly J., Wiholm B., et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol 94 (1999) 3189-3196
71. Neutel C., and Appel W. The effect of alcohol abuse on the risk of NSAID-related gastrointestinal events. Ann Epiderniol 10 (2000) 246-250
72. Celebrex (celecoxib) [prescribing information]
73. http://www.drugs.com/celebrex.html Accessed August 16, 2007
74. Brater D., Harris C., Redfern J., and Gertz B. Renal effects of COX-2-selective inhibitors. Am J Nephrol 21 (2001) 1-15
75. Curtis S., Ng J., Yu Q., et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 26 (2004) 70-83
76. Houston M. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 90 (1991) 42S-47S
77. Radack K., Deck C., and Bloomfield S. Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med 107 (1987) 628-635
78. Abate M., Layne R., Neely J., and D'Alessandri R. Effect of naproxen and sulindac on blood pressure response to atenolol. DICP 24 (1990) 810-813
79. Pope J., Anderson J., and Felson D. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153 (1993) 477-484
80. MacFarlane L., Orak D., and Simpson W. NSAIDs, antihypertensive agents and loss of blood pressure control. Am Fam Physician 51 (1995) 849-856
81. Izhar M., Alausa T., Folker A., et al. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics. Hypertension 43 (2004) 573-577
82. Nietert P., Ornstein S., Dickerson L., and Rothenberg R. Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. Pharmacotherapy 23 (2003) 1416-1423
83. Grover S., Coupal L., and Zowall H. Treating osteoarthritis with cyclo-oxygenase-2-specific inhibitors: What are the benefits of avoiding blood pressure destabilization?. Hypertension 45 (2005) 92-97
84. Whelton A., White W., Bello A., et al., for the SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteo-arthritis. Am J Cardiol 90 (2002) 959-963
85. Borchers A., Keen C., Cheema G., and Gershwin M. The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum 34 (2004) 465-483
86. Thyss A., Milano G., Kubar J., et al. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1 (1986) 256-258
87. Frenia M., and Long K. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother 26 (1992) 234-237
88. Hoekstra M., van Ede A., Haagsma C., et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 62 (2003) 423-426
89. Karim A., Tolbert D., Hunt T., et al. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 26 (1999) 2539-2543
90. Skeith K., Russell A., Jamali F., et al. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. J Rheumatol 17 (1990) 1008-1010
91. Stewart C., Fleming R., Arkin C., and Evans W. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clin Pharmacol Ther 47 (1990) 540-546
92. Frolich J., Leftwich R., Ragheb M., et al. Indomethacin increases plasma lithium. BMJ 1 (1979) 1115-1116
93. Ragheb M. Ibuprofen can increase serum lithium level in lithium-treated patients. J Clin Psychiatry 48 (1987) 161-163
94. Ragheb M., and Powell A. Lithium interaction with sulindac and naproxen. J Clin Psychopharmacol 6 (1986) 150-154
95. Khan I. Lithium and non-steroidal anti-inflammatory drugs. BMJ 302 (1991) 1537-1538
96. Phelan K., Mosholder A., and Lu S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry 64 (2003) 1328-1334
97. Rossat J., Maillard M., Nussberger J., et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66 (1999) 76-84
98. Reimann I., Diener U., and Frolich J. Indomethacin but not aspirin increases plasma lithium ion levels. Arch Gen Psychiatry 40 (1983) 283-286
99. Reimann I., Golbs E., Fischer C., and Frolich J. Influence of intravenous acetylsalicylic acid and sodium salicylate on human renal function and lithium clearance. Eur J Clin Pharmacol 29 (1985) 435-441
100. Ragheb M. The clinical significance of lithium-nonsteroidal antiinflammatory drug interactions. J Clin Psychopharmacol 10 (1990) 350-354
101. Serebruany V. Selective serotonin reuptake inhibitors and increased bleeding risk: Are we missing something?. Am J Med 119 (2006) 113-116
102. Dalton S., Johansen C., Mellemkjaer L., et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: A population-based cohort study. Arch Intern Med 163 (2003) 59-64
103. De Abajo F., Rodriguez L., and Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: Population based case-control study. BMJ 319 (1999) 1106-1109
104. Lesch K., Wolozin B., Murphy D., and Reiderer P. Primary structure of the human platelet serotonin uptake site: Identity with the brain serotonin transporter. J Neurochem 60 (1993) 2319-2322
105. Langman M., Weil J., Wainwright P., et al. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. [published correction appears in Lancet. 1994;343:1302]. Lancet 343 (1994) 1075-1078
106. Hippisley-Cox J., Coupland C., and Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: Population based nested case-control analysis. BMJ 331 (2005) 1310-1316
107. van Walraven C., Mamdani M., Wells P., and Williams J. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: Retrospective cohort study. BMJ 323 (2001) 655-658
108. de Jong J., van den Berg P., Tobi H., and de Jong-van den Berg L. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 55 (2003) 591-595
109. Tata L., Fortun P., Hubbard R., et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal antiinflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?. Aliment Pharmacol Ther 22 (2005) 175-181
110. Helin-Salmivaara A., Huttunen T., Gronroos J., et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: A case-control study in the general population. Eur J Clin Pharmacol 63 (2007) 403-408
111. Flockhart DA. Cytochrome P450 drug interaction table
112. http://medicine.iupui.edu/flockhart/ Accessed August 18, 2007
113. Mico J., Ardid D., Berrocoso E., and Eschalier A. Antidepressants and pain. Trends Pharmacol Sci 27 (2006) 348-354
114. Dentali F., Douketis J., Woods K., et al. Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial. Ann Pharmacother 40 (2006) 1241-1247
115. Jiang X., Williams K., Liauw W., et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 59 (2005) 425-432
116. Malhi H., Atac B., Daly A., and Gupta S. Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgrad Med J 80 (2004) 107-109
117. Christensen H., Baker M., Tucker G., and Rostami-Hodjegan A. Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. J Pharm Sci 95 (2006) 2778-2787
118. Scheen A. Drug interactions of clinical importance with antihyperglycemic agents. Drug Sag 28 (2005) 601-631
119. Shorr R., Ray W., Daugherty J., and Griffin M. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 153 (1993) 1665-1670
120. Chung L., Chakravarty E., Kearns P., et al. Bleeding complications in patients on celecoxib and warfarin. J Clin Pharm Ther 30 (2005) 471-477
121. Wilner K., Rushing M., Walden C., et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volu nteers. J Clin Pharmacol 42 (2002) 1027-1030
122. Battistella M., Mamdami M., Juurlink D., et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 165 (2005) 189-192
123. Altman R., Hochberg M., Moskowitz R., Schnitzer T., and for the American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43 (2000) 1905-1915
124. Gebauer M., Nyfort-Hansen K., Henschke P., and Gallus A. Warfarin and acetaminophen interaction. Pharmacotherapy 23 (2003) 109-112
125. Mahe I., Bertrand N., Drouet L., et al. Paracetamol: A haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol 59 (2005) 371-374
126. Mahe I., Bertrand N., Drouet L., et al. Interaction between paracetamol and warfarin in patients: A double-blind, placebo-controlled, randomized study. Haematologica 91 (2006) 1621-1627
127. Parra D., Beckey N., and Stevens G. The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy. Pharmacotherapy 27 (2007) 675-683
128. Scher M., Huntington N., and Vitillo J. Potential interaction between tramadol and warfarin. Ann Pharmacother 31 (1997) 646-647
129. Sabbe J., Sims P., and Sims M. Tramadol-warfarin interaction. Pharmacotherapy 18 (1998) 871-873
130. Derry S., and Loke Y. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. BMJ 321 (2000) 1183-1187
131. Serebruany V., Steinhubl S., Berger P., et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 95 (2005) 1218-1222
132. Loke Y., Bell A., and Derry S. Aspirin for the prevention of cardiovascular disease: Calculating benefit and harm in the individual patient. Br J Clin Pharmacol 55 (2003) 282-287
133. Goldstein J., Bello A., Spalding W., et al. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: Pooled analysis of 2 trials. J Rheumatol 32 (2005) 111-117
134. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310 (1995) 827-830
135. Schnitzer T., Burmester G., Mysler E., et al., for the TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet 364 (2004) 665-674
136. Catella-Lawson F., Reilly M., Kapoor S., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
137. Feldman M., and Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol 84 (1999) 404-409
138. Reilly I., and FitzGerald G. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 69 (1987) 180-186
139. Cryer B., Berlin R., Cooper S., et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther 27 (2005) 185-191
140. MacDonald T., and Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361 (2003) 573-574
141. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321 (1989) 129-135
142. Kurth T., Glynn R., Walker A., et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108 (2003) 1191-1195
143. Kimmel S., Berlin J., Reilly M., et al. The effects of nonelective non-aspirin non-steroidal antiinflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coil Cardiol 43 (2004) 985-990
144. Beaver W. Aspirin and acetaminophen as constituents of analgesic combinations. Arch Intern Med 141 (1981) 293-300
145. Cooper S., Precheur H., Rauch D., et al. Evaluation ofoxycodone and acetaminophen in treatment of postoperative dental pain. Oral Surg Oral Med Oral Pathol 50 (1980) 496-501
146. McQuay H., and Edwards J. Meta-analysis of single dose oral tramadol plus acetaminophen in acute postoperative pain. Eur J Anaesthesiol 20 Suppl 28 (2003) 19-22
147. Collins S., Edwards J., Moore R., and McQuay H. Single dose dextropropoxyphene, alone and with paracetamol (acetaminophen), for post-operative pain. Cochrane Database Syst Rev 3 (2007) CD001440
148. Moore A., Collins S., Carroll D., and McQuay H. Paracetamol with and without codeine in acute pain: A quantitative systematic review. Pain 70 (1997) 193-201
149. Borison H. Central nervous respiratory depressants-narcotic analgesics. Pharmacol Ther [B] 3 (1977) 227-237
150. Nabeshima T., Matsuno K., and Kameyama T. Involvement of different opioid receptor subtypes in electric shock-induced analgesia and motor suppression in the rat. Eur J Pharmacol 114 (1985) 197-207
151. Spiller H. Postmortem oxycodone and hydrocodone blood concentrations. J Forensic Sci 48 (2003) 429-431
152. Reeves R., and Mack J. Possible dangerous interaction of oxycontin and carisoprodol. Am Faro Physician 67 (2003) 941-942
153. Gerostamoulos J., Burke M., and Drummer O. Involvement of codeine in drug-related deaths. Am J Forensic Med Pathol 17 (1996) 327-335
154. Schifano F., Zamparutti G., Zambello F., et al. Review of deaths related to analgesic- and cough suppressantopioids; England and Wales 1996-2002. Pharmacopsychiatry 39 (2006) 185-191
155. Davis G., and Alexander C. A review of carisoprodol deaths in Jefferson County, Alabama. South Med J 91 (1998) 726-730
156. Clarot F., Goulle J., Vaz E., and Proust B. Fatal overdoses of tramadol: Is benzodiazepine a risk factor of lethality?. Forensic Sci Int 134 (2003) 57-61
157. Michaud K., Augsburger M., Romain N., et al. Fatal overdose of tramadol and alprazolam. Forensic Sci Int 105 (1999) 185-189
158. Desmeules J., Gascon M., Dayer P., and Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 41 (1991) 23-26
159. Enggaard T., Poulsen L., Arendt-Nielsen L., et al. The analgesic effect oftramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 102 (2006) 146-150
160. Lee C., McTavish D., and Sorkin E. Tramadol: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 46 (1993) 313-340
161. Stamer U., Lehnen K., Hothker F., et al. Impact oFCYP2D6 genotype on postoperative tramadol analgesia. Pain 105 (2003) 231-238
162. Brousseau D., McCarver D., Drendel A., et al. The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr 150 (2007) 623-626
163. Hutchinson M., Menelaou A., Foster D., et al. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 57 (2004) 287-297
164. Jannetto P., Wong S., Gock S., et al. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: Genotyping cytochrome P450 2D6 for oxycodone cases. J Anal Toxicol 26 (2002) 438-447
165. Garrido M., Sayar O., Segura C., et al. Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: Role ofcytochrome P450 2D activity. J Pharmacol Exp Ther 305 (2003) 710-718
166. Sindrup S., Arendt-Nielsen L., Brosen K., et al. The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol 42 (1992) 587-591
167. Crewe H., Lennard M., Tucker G., et al. The effect of selective sero- tonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34 (1992) 262-265
168. Laugesen S., Enggaard T., Pedersen R., et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 77 (2005) 312-323
169. John A., and Koloth R. Severe serotonin toxicity and manic switch induced by combined use of tramadol and paroxetine. Aust N Z J Psychiatry 41 (2007) 192-193
170. Lantz M., Buchalter E., and Giambanco V. Serotonin syndrome following the administration of tramadol with paroxetine. Int J Geriatr Psychiatry 13 (1998) 343-345
171. Egberts A., ter Borgh J., and Brodie-Meijer C. Serotonin syndrome attributed to tramadol addition to paroxetine therapy. Int Clin Psychopharmacol 12 (1997) 181-182
172. Mason B., and Blackburn K. Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother 31 (1997) 175-177
173. Lange-Asschenfeldt C., Weigmann H., Hiemke C., and Mann K. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: Plasma level-correlated symptomatology. J Clin Psychopharmacol 22 (2002) 440-441
174. Kesavan S., and Sobala G. Serotonin syndrome with fluoxetine plus tramadol. J R Soc Med 92 (1999) 474-475
175. Clark R., Wei E., and Anderson P. Meperidine: Therapeutic use and toxicity. J Emerg Med 13 (1995) 797-802
176. Denton P., Borrelli V., and Edwards N. Dangers of monoamine oxidase inhibitors. Br Med J 2 (1962) 1752-1753
177. Zornberg G., Bodkin J., and Cohen B. Severe adverse interaction between pethidine and selegiline. Lancet 337 (1991) 246
178. Gillman P. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 95 (2005) 434-441